Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-α induces significant tumor regression

Cancer Gene Therapy

Volumn 5, Issue 6, 1998, Pages 371-379

  Wright, Philip ^a   Zheng, Changyu ^b   Moyana, Terence ^a   Xiang, Jim ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c Saskatoon Cancer Center   (Canada)

Author keywords

Fusion protein; Recombinant adenovirus; Tumor necrosis factor

Indexed keywords

CANCER VACCINE; DNA VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; RM4 TNF PROTEIN, RECOMBINANT; RM4-TNF PROTEIN, RECOMBINANT; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL CULTURE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; KINETICS; LACTOSE OPERON; METABOLISM; MOUSE; MULTIPLE MYELOMA; NUDE MOUSE; REPORTER GENE; TIME;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, REPORTER; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KINETICS; LAC OPERON; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA;

EID: 0032197465     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Blankenstein T, Qin Z, Uberla K, Muller W, Rosen H, Volk H, Diamantstein T. Tumor suppression after tumor cell-targeted tumor necrosis factor gene transfer. J Exp Med. 1991;173:1047-1052.
2. Qi Y, Chen Y, Xiang J. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J Interferon Cytokine Res. 1996;16:771-776.
3. Koshita Y, Lu Y, Fujii S, et al. Efficiency of TNF-α gene-transduced tumor cells in treatment of established in vivo tumor. Int J Cancer. 1995;63:130-135.
4. Xiang J. Antitumor vaccination with gene-transduced tumor cells expressing a fusion protein RM4/IFN-γ. Cancer Biother Radiopharm. 1997;12:123-130.
5. Colombo M, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G. Granulocyte colonystimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med. 1991;173: 889-897.
6. Allione A, Consalvo M, Manni P, Cavallo F, Giovarelli M, Forni G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF, GM-CSF, and IFN gene or admixed with conventional adjuvants. Cancer Res. 1994;54:6022-6026.
7. Brody S, Jaffee H, Han S, Wersto R, Crystal R. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther. 1994;5:437-447.
8. Chen S, Shine H, Goodman J, Grossman R, Woo A. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
9. Fujiwara T, Grimm E, Mukhopahyay T, et al. Induction of chemosensitivity in human lung cancer cells by adenovirusmediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287-2291.
10. Smythe W, Kaiser L, Hwang H. Successful adenovirusmediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994;57:1395-1401.
11. Bett A, Haddara W, Prevec L, Graham F. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early region 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
12. Neve R. Adenovirus vectors enter the brain. Trends Neurosci. 1993;16:251-254.
13. Engelhardt J, Simon R, Yang Y, et al. Adenovirusmediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther. 1993; 4:759-769.
14. Zabner J, Couture L, Gregory R, Graham S, Smith A, Welsh M. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell. 1993;75:207-216.
15. Addison C, Braciak T, Ralston R, Muller W, Gauldie J, Graham F. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA. 1995;92:8522-8526.
16. Toloza Em, Hunt K, Swisher S, McBride W, Lau R, Pang S, Rhoades K, Drake T, Belldegrun A, Economou J. In vivo cancer gene therapy with a recombinant interleukin 2 adenovirus vector. Cancer Gene Ther. 1996;3:11-17.
17. Tanaka F, Abe M, Akiyoshi T, Normura T, Sugimachi K, Kishimoto T, Suzuki T, Okada M. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the IL-6 gene using adenovirus vector. Cancer Res. 1997;57:1335-1343.
18. Zhang J, Hu C, Geng Y, Blatt L, Taylor M. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther. 1997;3:31-38.
19. 2 and tumor necrosis factor. J Biotechnol. 1997;53:3-12.
20. Xiang J, Moyana T, Karla J, Hamilton T, Qi Y. Construction and characterization of a high-affinity chimeric anticolorectal carcinoma antibody ccM4. Mol Biother. 1992;4: 174-183.
21. Van Doren K, Hanahan D, Gluzman Y. Infection of eukaryotic cells by helper-independent recombinant adenoviruses: early region I is not obligatory for integration of viral DNA. J Virol. 1984;50:606-614.
22. Mittereder N, Yei S, Bachurski C, Cuppoletti J, Whitsett J, Tolstoshev P, Trapnell B. Evaluation of the efficacy and safety of in vitro adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther. 1994;5:717-729.
23. Smith T, Mehaffey M, Kayda D, Saunders J, Yei S, Trapnell B, Kaleko M. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet. 1993;5:397-402.
24. Zhang W, Koch P, Roth J. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechiques. 1995;18:444-447.
25. Cusack J, Spitz F, Nguyen D, Zhang W, Christiano R, Roth J. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther. 1996;3:245-249.
26. Talmadge J, Phillips H, Schneider M. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res. 1988;48:544-550.
27. Shalaby M, Aggrarwal B, Rinderknecht E, et al. Activation of human polymorphonuclear neutrophil function by IFN-γ and TNF. J Immunol. 1985;135:2069-2073.
28. Robinet E, Branelec D, Termijtelen A, et al. Evidence for TNF involvement in the optimal induction of class I allospecific cytotoxic T cells. J Immunol. 1990;144:4555-4561.
29. Creasey A, Reynolds M, and Laird W. Cures and partial regression of murine and human tumors by recombinant human necrosis factor. Cancer Res. 1986;46:5687-5690.
30. Asher A, Mule J, Reichert C, Shiloni E, Rosenberg S. Studies on the antitumor efficacy of systemically administered recombinant TNF against several murine tumors in vivo. J Immunol. 1987;138:963-974.
31. Freinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously administered recombinant tumor necrosis factor in cancer patients. J Clin Oncol 1986;6:1328-1334.
32. Moritz T, Niederle N, Baumann J, et al. Phase I study of recombinant human tumor necrosis factor in advanced malignant disease. Cancer Immunol Immunother. 1989;29: 144-149.
33. Sherman M, Spriggs D, Arthur K, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988;6:344-354.
34. Creaven P, Plager J, Dupers S, et al. Phase I clinical trial of recombinant human necrosis factor. Cancer Chemother Phannacol. 1987;20:137-144.
35. Boviatsis E, Chase M, Wei M, et al. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus. Hum Gene Ther. 1994;5:183-191.